Filing Flows › Nutra Pharma (NPHC) › Q3 2025
Nutra Pharma (NPHC) Q3 2025 earnings results (third quarter 2025)
10-Q filed Apr 6, 2026
Nutra Pharma (NPHC) reported revenue of $70K for the third quarter 2025 (Q3 2025), -6% from a year earlier and -17% from the quarter before. Operating margin was -506.9%, net loss $524K (745.3% of revenue).
Nutra Pharma, Q3 2025: revenue $70K (-6% year over year), operating margin -506.9%, net loss $524K, operating cash flow −$251K. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $70K | -17% | -6% |
| Operating profit | −$356K | — | — |
| Net earnings | −$524K | -242% | — |
| Operating cash flow | −$251K | — | — |
What changed
Revenue was $70K in Q3 2025, down 6% year over year and down 17% from the previous quarter.
Gross margin was 91.9%, down 2.3 points from a year earlier. Operating costs exceeded revenue by $356K, an operating margin of -506.9%. Operating expenses grew 65% against a revenue fall of 6%. The quarter ended with a net loss of $524K, after a profit of $370K the previous quarter.
Operating cash flow was −$251K. Non-cash charges added back $3K of depreciation and $8K of share-based compensation. Working capital and other items added $261K.
Questions
What was Nutra Pharma's revenue in the third quarter 2025?
Nutra Pharma (NPHC) reported revenue of $70K for the third quarter 2025 (Q3 2025), -6% from a year earlier and -17% from the quarter before.
Was Nutra Pharma profitable in the third quarter 2025?
Operating loss was $356K (-506.9% of revenue) and net loss $524K.
Source: Nutra Pharma 10-Q on SEC EDGAR.